1206487-35-5

Basic information

• Product Name: 4,6-dibromopyridazin-3-amine
• Synonyms: 4,6-dibromopyridazin-3-amine;3-Amino-4,6-dibromopyridazine;4,6-Dibromo-3-pyridazinamine
• CAS NO: 1206487-35-5
• Molecular Formula: C₄H₃Br₂N₃
• Molecular Weight: 253
• Mol File: 1206487-35-5.mol

Chemical Properties

• Boiling Point: 376.6±37.0 °C(Predicted)
• Appearance: /
• Density: 2.287±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.93±0.10(Predicted)
• CAS DataBase Reference: 4,6-dibromopyridazin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dibromopyridazin-3-amine(1206487-35-5)
• EPA Substance Registry System: 4,6-dibromopyridazin-3-amine(1206487-35-5)

Safety Data

• Hazardous Substances Data: 1206487-35-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4,6-dibromopyridazin-3-amine is utilized as an intermediate in the production of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the synthesis of drugs that target specific biological pathways or mechanisms, potentially leading to the development of new therapeutic agents.
Used in Agrochemicals Production:
In the agrochemical industry, 4,6-dibromopyridazin-3-amine is employed as an intermediate for the synthesis of various agrochemicals. Its chemical properties make it suitable for the development of compounds that can be used in crop protection and other agricultural applications, contributing to enhanced crop yields and protection against pests and diseases.
Used in Industrial Material Manufacturing:
4,6-dibromopyridazin-3-amine may also have industrial applications in the manufacturing of certain materials. Its specific chemical structure can contribute to the development of new materials with unique properties, such as improved stability, reactivity, or other desirable characteristics, which can be beneficial in various industrial processes.

Upstream product

• 88497-27-2 6-bromopyridazin-3-amine 
• 187973-60-0 6-iodopyridazine-3-amine 

Downstream Products

• 1402608-82-5 tert-butyl (1-{4-[3-phenyl-6,8-dibromoimidazo[1,2-b]pyridazin-2-yl]-phenyl}cyclobutyl)carbamate 
• 1206487-36-6 6,8-dibromoimidazo[1,2-b]pyridazine 

Relevant articles and documents

PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.

SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER

The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.